Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

Peterson JT, Stacey HL, MacNair JE, Li J, Hartzel JS, Sterling TM, Benner P, Tamms GM, Musey LK

Open source

DOI
10.1080/21645515.2018.1532250
Published
2019
Container
Human vaccines & immunotherapeutics
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/21645515.2018.1532250,
  title = {Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.},
  author = {Peterson JT and Stacey HL and MacNair JE and Li J and Hartzel JS and Sterling TM and Benner P and Tamms GM and Musey LK},
  year = {2019},
  journal = {Human vaccines \& immunotherapeutics},
  doi = {10.1080/21645515.2018.1532250},
  url = {https://doi.org/10.1080/21645515.2018.1532250}
}

RIS

TY  - JOUR
TI  - Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
AU  - Peterson JT
AU  - Stacey HL
AU  - MacNair JE
AU  - Li J
AU  - Hartzel JS
AU  - Sterling TM
AU  - Benner P
AU  - Tamms GM
AU  - Musey LK
PY  - 2019
JO  - Human vaccines & immunotherapeutics
DO  - 10.1080/21645515.2018.1532250
UR  - https://doi.org/10.1080/21645515.2018.1532250
ER  - 

APA

JT, P., HL, S., JE, M., J, L., JS, H., TM, S., P, B., GM, T., & LK, M. (2019). Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.. Human vaccines & immunotherapeutics. https://doi.org/10.1080/21645515.2018.1532250

Source records